RNAi Therapeutics
•23 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (23)
%
| Company | Market Cap | Price |
|---|---|---|
|
RNAi therapeutics and RNA-targeted therapies are part of Lilly's cutting-edge platforms.
|
$789.93B |
$833.49
-2.86%
|
|
Amvuttra represents an RNAi Therapeutics program in the portfolio.
|
$120.19B |
$98.46
|
|
RNAi Therapeutics captures the C5 siRNA programs and related genetic-silencing approaches.
|
$60.96B |
$564.63
-0.82%
|
|
Alnylam's core offerings are RNA interference therapeutics (AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO), defining the primary product category as RNAi Therapeutics.
|
$60.04B |
$460.46
+0.04%
|
|
QALSODY (tofersen) and zorevunersen are nucleic-acid therapies, aligning with RNA-based therapeutics.
|
$21.48B |
$146.57
-2.29%
|
|
RNA interference (siRNA) based therapeutics are its core modality via the AOC platform.
|
$5.18B |
$42.95
+3.74%
|
|
Direct product category: Arrowhead's core TRiM RNAi therapeutics platform and pipeline drive its value.
|
$4.89B |
$35.41
-1.64%
|
|
Collaboration with Stoke Therapeutics involves RNA-based CNS rare-disease programs, aligning with RNAi therapeutics.
|
$3.52B |
$21.05
-0.94%
|
|
AG-236 is an siRNA therapeutic, placing the company in the RNAi Therapeutics modality.
|
$2.35B |
$40.61
-4.47%
|
|
Sarepta's siRNA/RNAi platform represents a scalable, multi-indication therapeutics approach with preclinical assets and Arrowhead collaboration.
|
$2.17B |
$22.11
-4.49%
|
|
Payload delivery includes oligonucleotides, aligning with RNA interference/oligonucleotide–based therapeutics.
|
$1.60B |
$14.05
-0.57%
|
|
Imdusiran (AB-729) is a proprietary RNA interference therapeutic directly developed by Arbutus for chronic HBV, making RNAi therapeutics a core product category.
|
$831.23M |
$4.34
-1.14%
|
|
Elebsiran is an RNAi-based therapeutic component used in HDV/HBV regimens.
|
$758.93M |
$5.49
+5.98%
|
|
Company's lead assets and platform focus on RNA interference–based therapeutics (ddRNAi), i.e., RNAi Therapeutics.
|
$381.96M |
$14.92
+5.89%
|
|
Silence's core business is RNAi therapeutics, anchored by its mRNAi GOLD GalNAc siRNA platform and wholly-owned programs.
|
$235.84M |
$5.00
-7.41%
|
|
RNA-based therapeutics (oligonucleotide delivery) is a key modality supported by the EEV platform.
|
$231.14M |
$6.09
-10.44%
|
|
Codexis is pivoting to RNAi therapeutics manufacturing using the ECO Synthesis platform, aiming to become a direct supplier of siRNA materials.
|
$214.57M |
$2.59
-7.50%
|
|
PGN-EDODM1 is an RNA-targeting oligonucleotide therapeutic, aligning PepGen with RNA-based therapeutics.
|
$154.28M |
$4.71
-3.78%
|
|
Direct RNA-based therapeutics platform focusing on upregulating gene expression via regRNA-targeting antisense oligos.
|
$61.09M |
$3.03
+1.00%
|
|
PLEX can encapsulate siRNA, suggesting potential RNAi Therapeutics applications in its pipeline.
|
$15.11M |
$3.15
-3.96%
|
|
The company licenses RNA interference assets (siRNA) and pursues RNAi therapeutics development as part of its pipeline.
|
$13.56M |
$1.44
-4.64%
|
|
RNA interference (RNAi) based therapeutics are a core modality in their pipeline (siRNA targeting PD-L1, miR-10b).
|
$8.81M |
$10.56
-1.45%
|
|
RNA interference therapies (DiffronC and related assets) place RGBP in RNAi Therapeutics.
|
$703985 |
$0.02
-41.18%
|
Loading industry metrics...
Loading comparison data...
